EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Amastigote and Trypomastigote Phases: Multi‐Epitope Vaccine Strategy Against Trypanosoma cruzi

Maria Karolaynne da Silva iD, Caio Patrício de Souza Sena, Davi Serradella Vieira, Magdi E A Zaki, Leow Chiuan Yee, Shahina Akter iD, Umberto Laino Fulco, Jonas Ivan Nobre Oliveira, João Firmino Rodrigues-Neto iD

Biotechnology and Applied Biochemistry · 2026

DOI: 10.1002/bab.70185 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biotechnology and Applied Biochemistry, 2026. Verfasst von Maria Karolaynne da Silva und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biophysics and Pharmacology, Bioscience Center, Federal University of Rio Grande Do Norte, Natal, Brazil. Hauptthemen laut MEDLINE: Trypanosoma cruzi, Protozoan Vaccines, Epitopes, B-Lymphocyte, Chagas Disease. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Effective vaccines against Trypanosoma cruzi , the causative agent of Chagas disease, are urgently needed. Here, we report the design and in silico validation of a novel multiepitope vaccine construct targeting the key surface proteins ASP‐2 and gp82. Using a comprehensive immunoinformatics pipeline, we identified and selected 38 potent T‐cell (CTL/HTL) and B‐cell epitopes, ensuring high antigenicity, immunogenicity, and safety. The final chimeric protein, integrated with adjuvants and stabilizing linkers, demonstrated favorable physicochemical properties, high solubility, and was predicted to be non‐allergenic and non‐toxic, with a significant population coverage of approximately 62% in Latin America. Structural modeling and refinement confirmed a stable tertiary structure. Crucially, molecular docking predicted high‐affinity interactions with the immune receptors TLR2 and TLR4 (docking scores: −1360.4 and −1278.7, respectively). The stability and flexibility of these vaccine–receptor complexes were further validated by 300 ns molecular dynamics simulations. Finally, codon optimization and in silico cloning projected high expression potential in an Escherichia coli system. Immune simulations predicted robust responses: Innate (elevated cytokines, dendritic cell activation), humoral (IgG/IgM production), and cellular (CD4+/CD8+/memory T‐cell activation) across simulated doses. These findings strongly support the potential of this vaccine candidate and provide a solid foundation for its further preclinical development against T. cruzi .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Trypanosoma cruziProtozoan VaccinesEpitopes, B-LymphocyteChagas DiseaseEpitopes, T-LymphocyteEpitopesAnimalsMolecular Docking SimulationProtein Subunit VaccinesImmunoinformaticsMolecular Dynamics Simulation

Stichwörter der Autor:innen

Chagas diseaseTrypanosoma cruziimmunoinformaticsmulti‐epitope vaccine

Substanzen

Protozoan VaccinesEpitopes, B-LymphocyteProtein Subunit VaccinesEpitopes, T-LymphocyteEpitopes

Autor:innen und Institutionen

  • Department of Biophysics and Pharmacology, Bioscience Center, Federal University of Rio Grande Do Norte, Natal, Brazil.
  • Chemistry Institute, Federal University of Rio Grande Do Norte, Natal, Brazil.
  • Department of Chemistry, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
  • Institute For Research in Molecular Medicine, Universiti Sains Malaysia, Kelantan, Malaysia.
  • Bangladesh Council of Scientific & Industrial Research (BCSIR), Dhaka, Bangladesh.
  • Department of Clinical and Toxicological Analysis, Federal University of Rio Grande Do Norte, Natal, Brazil.

ORCID-Profile: Maria Karolaynne da Silva, Shahina Akter, João Firmino Rodrigues-Neto

Förderung

  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Zitieren

APA

Silva, M. K. D., Sena, C. P. S., Vieira, D. S., Zaki, M. E. A., Yee, L. C., Akter, S., Fulco, U. L., Oliveira, J. I. N., & Rodrigues-Neto, J. F. (2026). Targeting Amastigote and Trypomastigote Phases: Multi‐Epitope Vaccine Strategy Against Trypanosoma cruzi. Biotechnology and Applied Biochemistry. https://doi.org/10.1002/bab.70185

Vancouver

Silva MKD, Sena CPS, Vieira DS, Zaki MEA, Yee LC, Akter S, et al. Targeting Amastigote and Trypomastigote Phases: Multi‐Epitope Vaccine Strategy Against Trypanosoma cruzi. Biotechnology and Applied Biochemistry. 2026. doi:10.1002/bab.70185

BibTeX
@article{Silva2026,
  author = {Silva, Maria Karolaynne da and Sena, Caio Patrício de Souza and Vieira, Davi Serradella and Zaki, Magdi E A and Yee, Leow Chiuan and Akter, Shahina and Fulco, Umberto Laino and Oliveira, Jonas Ivan Nobre and Rodrigues-Neto, João Firmino},
  title = {Targeting Amastigote and Trypomastigote Phases: Multi‐Epitope Vaccine Strategy Against Trypanosoma cruzi},
  journal = {Biotechnology and Applied Biochemistry},
  year = {2026},
  doi = {10.1002/bab.70185}
}
Kostenlos starten →